News

Healio18h
FDA rejects Genentech’s glofitamab-gxbm for DLBCL, stymied by insufficient evidence
The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...
The American Journal of Managed Care20h
FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL
The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...
Fierce Pharma21h
FDA rejects Roche's Columvi in earlier diffuse large B-cell lymphoma, citing lackluster US data
The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...
Exercise could ease symptoms for people with chronic lymphocytic leukaemia (CLL) – new study
CLL can mean fatigue, fear and years of waiting but new research shows that staying active helps people feel better – and ...
Targeted Oncology1d
Primary Refractory DLBCL Status Takes on Greater Significance in CAR T Era
During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...
The American Journal of Managed Care1d
After CAR T in Mantle Cell Lymphoma, Choices and a Robust Pipeline
Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.
SurvivorNet on MSN4d
FDA Loosens Safety Requirements For CAR T-Cell Therapies, Paving The Way For Many More Blood Cancer Patients To Access Innovative Treatment
The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.